S L Walmsley

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi Treatment of HIV infection in pregnant women: antiretroviral management options
    Mona R Loutfy
    Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
    Drugs 64:471-88. 2004
  2. ncbi Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
    Darrell H S Tan
    University Health Network, 585 University Ave, 13N 1323, Toronto, Ontario, M5G 2N2 Canada
    Trials 11:113. 2010
  3. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  4. ncbi Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men
    Sharon L Walmsley
    University Health Network, University of Toronto, Canada
    AIDS 23:429-31. 2009
  5. ncbi Opt in or opt out: what is optimal for prenatal screening for HIV infection?
    Sharon Walmsley
    University of Toronto, Toronto, Ont
    CMAJ 168:707-8. 2003
  6. ncbi A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy
    Sharon Walmsley
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    HIV Clin Trials 9:314-23. 2008
  7. ncbi Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)
    Sharon L Walmsley
    Division of Clinical Investigation and Human Physiology, University of Toronto, Toronto, ON, Canada
    J Acquir Immune Defic Syndr 47:429-40. 2008
  8. ncbi A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164)
    Sharon L Walmsley
    Department of Medicine, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:418-25. 2007
  9. ncbi Protease inhibitor-based regimens for HIV therapy: safety and efficacy
    Sharon Walmsley
    Division of Infectious Diseases, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:S5-13; quiz S28-31. 2007
  10. ncbi Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide
    Sharon Walmsley
    University of Toronto, Toronto, Ontario, Canada
    J Infect Dis 188:1827-33. 2003

Detail Information

Publications65

  1. ncbi Treatment of HIV infection in pregnant women: antiretroviral management options
    Mona R Loutfy
    Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Quebec, Canada
    Drugs 64:471-88. 2004
    ....
  2. ncbi Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
    Darrell H S Tan
    University Health Network, 585 University Ave, 13N 1323, Toronto, Ontario, M5G 2N2 Canada
    Trials 11:113. 2010
    ..Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression...
  3. ncbi Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  4. ncbi Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men
    Sharon L Walmsley
    University Health Network, University of Toronto, Canada
    AIDS 23:429-31. 2009
    ..Significantly greater increases in CD4 cell count (+81.2 vs. +48.6; P = 0.0012) were observed in women at week 48...
  5. ncbi Opt in or opt out: what is optimal for prenatal screening for HIV infection?
    Sharon Walmsley
    University of Toronto, Toronto, Ont
    CMAJ 168:707-8. 2003
  6. ncbi A prospective study of body fat redistribution, lipid, and glucose parameters in HIV-infected patients initiating combination antiretroviral therapy
    Sharon Walmsley
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    HIV Clin Trials 9:314-23. 2008
    ..To prospectively determine incidence, prevalence, and extent of lipodystrophy (LD) and associated metabolic changes...
  7. ncbi Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51)
    Sharon L Walmsley
    Division of Clinical Investigation and Human Physiology, University of Toronto, Toronto, ON, Canada
    J Acquir Immune Defic Syndr 47:429-40. 2008
    ..Given the limited treatment options for patients with high-level resistance, antiretroviral (ARV) regimens based on concomitant use of 2 ritonavir (RTV)-boosted protease inhibitors (PIs) were considered a therapeutic option...
  8. ncbi A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164)
    Sharon L Walmsley
    Department of Medicine, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:418-25. 2007
    ..The primary endpoint was the percentage of patients with a 3-month sustained HIV RNA level <50 copies/mL...
  9. ncbi Protease inhibitor-based regimens for HIV therapy: safety and efficacy
    Sharon Walmsley
    Division of Infectious Diseases, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 45:S5-13; quiz S28-31. 2007
    ..In this article, the evidence for the use of boosted PIs as early therapy is reviewed, with emphasis on data available from comparative randomized controlled trials...
  10. ncbi Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide
    Sharon Walmsley
    University of Toronto, Toronto, Ontario, Canada
    J Infect Dis 188:1827-33. 2003
    ..Safety was unaffected by the presence of positive antibody at any time point or change in level of antibody. There was no evidence that enfuvirtide cross-reactive gp41 antibody affects the efficacy or safety of enfuvirtide...
  11. ncbi Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection
    Sharon Walmsley
    Toronto Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
    N Engl J Med 346:2039-46. 2002
    ....
  12. ncbi Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults
    Sharon Walmsley
    University of Toronto, Toronto, Canada
    J Acquir Immune Defic Syndr 50:367-74. 2009
    ..Direct comparison of the efficacy and safety of different agents is needed to guide selection of optimal treatment regimens for therapy-naive HIV-1-infected patients...
  13. ncbi Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group
    S Walmsley
    Division of Infectious Diseases, Toronto Hospital, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 22:235-46. 1999
    ..Given the promise that retinoids show in the treatment of various hyperproliferative skin disorders and in vitro evidence of inhibition of proliferation of KS cells, a randomized, controlled clinical trial was conducted...
  14. ncbi The role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults
    Sharon Walmsley
    University of Toronto, EG 219, 200 Elizabeth Street, Toronto, ON, M5G 2C4, Canada
    Expert Rev Anti Infect Ther 1:389-401. 2003
    ..In addition, an expert opinion and commentary on the clinical applications of this drug is provided...
  15. ncbi Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression
    S Walmsley
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    Clin Infect Dis 32:1554-61. 2001
    ..Serum levels of azole and CD4 cell counts were also important parameters with regard to prediction of response. We conclude that in vivo and in vitro correlations compare favorably to studies of susceptibility testing in bacteria...
  16. ncbi Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection?
    Sharon Walmsley
    University of Toronto, Immunodeficiency Clinic, Toronto Hospital, Toronto, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 1:95-103. 2002
    ..Lastly, it identifies how the use of STIs could decrease drug burden and toxicity in patients receiving therapy...
  17. ncbi Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir
    S L Walmsley
    The Toronto Hospital Immunodeficiency Clinic, Department of Medicine, University of Toronto, Ontario, Canada
    Antivir Ther 6:47-54. 2001
    ..Response rates were lower in patients with increasing numbers of primary (P=0.045) or secondary (P=0.001) PI mutations. The addition of increasing numbers of reverse transcriptase mutations further impaired response rates (P=0.004)...
  18. ncbi Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis
    Sharon L Walmsley
    Department of Medicine, Toronto Hospital, University Health Network, University of Toronto, Canada
    HIV Clin Trials 7:1-9. 2006
    ..To determine the long-term safety of discontinuation of maintenance therapy for cytomegalovirus retinitis (CMVR) and to identify predictors for relapse...
  19. ncbi A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration
    M R Loutfy
    Department of Medicine, University of Toronto, Maple Leaf Medical Clinic, and Department of Family and Community Medicine, St Michael s Hospital, Toronto, Ontario, Canada
    HIV Med 8:427-32. 2007
    ..Tualatin, OR, USA) relative to standard needles...
  20. ncbi Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy
    S L Walmsley
    Toronto General Hospital Immunodeficiency Clinic, University Health Network, University of Toronto, Ontario, Canada
    AIDS 15:1581-4. 2001
    ..No patient with a viral isolate with an increased IC50 to efavirenz by virtual phenotype had a virological response..
  21. ncbi Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide
    M R Loutfy
    University of Toronto, Toronto, Ont, Canada
    Antiviral Res 75:58-63. 2007
    ..Further study is required to determine the clinical relevance of the clade related polymorphisms and the new mutations identified in the patients with virologic failure...
  22. ncbi CD36 deficiency induced by antiretroviral therapy
    Lena Serghides
    Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
    AIDS 16:353-8. 2002
    ..The molecular basis of lipodystrophy, a syndrome associated with HIV antiretroviral (ARV) therapy, remains unknown...
  23. ncbi Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections
    Darrell Tan
    Division of Infectious Diseases, University of Toronto, Toronto, Canada
    Expert Rev Anti Infect Ther 5:13-28. 2007
    ..Its favorable pharmacological and clinical characteristics have recently prompted investigators to explore its potential novel applications in HIV monotherapy and double-boosted regimens...
  24. ncbi Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class
    Troy Grennan
    Department of Infectious Diseases, McMaster University, St Joseph s Healthcare F506 1, Hamilton, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 8:354-63. 2009
    ..As new data emerge on the weighting of ETR's resistance-associated mutations (RAMs), investigators and clinicians will no doubt be able to further characterize its specific place in the HIV treatment armamentarium...
  25. ncbi Is chromium an important element in HIV-positive patients with metabolic abnormalities? An hypothesis generating pilot study
    Elaheh Aghdassi
    Department of Medicine, The University Health Network, The Toronto General Hospital, 200 Elizabeth St, Eaton Wing, 9 Floor, Room 217a, Toronto, Ontario, M5G 2C4, Canada
    J Am Coll Nutr 25:56-63. 2006
    ..Chromium plays a role in insulin sensitivity...
  26. ncbi Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-1-discordant partners
    D Bienzle
    Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada
    J Infect Dis 182:123-32. 2000
    ..These results suggest that a combination of factors, including cellular immunity, viral characteristics, and coreceptor integrity, may be involved in the persistent nontransmission of HIV...
  27. ncbi Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study
    Anita Rachlis
    Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Ontario, Canada
    HIV Clin Trials 6:203-12. 2005
    ..Pilot study to evaluate the effectiveness of a step-wise diarrhea management strategy for nelfinavir-associated diarrhea...
  28. ncbi The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults
    Robert Burgoyne
    Toronto General Hospital Immunodeficiency Clinic, Ontario, Canada
    Qual Life Res 14:981-90. 2005
    ..To investigate the relationship between lipodystrophy-specific symptom severity and wellbeing...
  29. ncbi Polypharmacy in HIV: impact of data source and gender on reported drug utilization
    Michelle D Furler
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    AIDS Patient Care STDS 18:568-86. 2004
    ..Our findings emphasize the complexity of pharmacotherapy in HIV and the need for comprehensive drug assessment, particularly because of the risks of drug-drug interactions and decreased adherence secondary to therapeutic complexity...
  30. ncbi A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy
    Rodrigo B Cavalcanti
    Department of Medicine and McLaughlin Rotman Centre, University Health Network, Toronto, ON, M5T 2S8, Canada
    J Infect Dis 195:1754-61. 2007
    ..Thiazolidinediones such as rosiglitazone may have benefit in ameliorating human immunodeficiency virus (HIV) lipoatrophy...
  31. ncbi Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada
    Michelle D Furler
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    AIDS Patient Care STDS 20:245-57. 2006
    ....
  32. ncbi Reassessment of enfuvirtide's role in the management of HIV-1 infection
    Patricia Marr
    University Health Network, Immunodeficiency Clinic, 13 North, Room 1314, 200 Elizabeth Street, Toronto, ON M5G2C4, Canada
    Expert Opin Pharmacother 9:2349-62. 2008
    ..This has led many clinicians to reevaluate the clinical utility of enfuvirtide...
  33. ncbi A randomized trial of N-acetylcysteine for prevention of trimethoprim-sulfamethoxazole hypersensitivity reactions in Pneumocystis carinii pneumonia prophylaxis (CTN 057). Canadian HIV Trials Network 057 Study Group
    S L Walmsley
    Department of Medicine, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr Hum Retrovirol 19:498-505. 1998
    ..N-acetylcysteine at a dose of 3 g twice daily could not be shown to prevent TMP-SMX hypersensitivity reactions in patients with HIV infection...
  34. ncbi Medicinal and recreational marijuana use by patients infected with HIV
    Michelle D Furler
    Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    AIDS Patient Care STDS 18:215-28. 2004
    ..The role of poverty in patient choice of medicinal marijuana despite access to care and the large proportion of women using marijuana for pain constitute areas for further study...
  35. ncbi Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research
    Rodrigo B Cavalcanti
    Department of Medicine, University of Toronto, and Division of General Internal Medicine, University Health Network, Toronto, Ontario, Canada
    J Clin Densitom 8:293-7. 2005
    ..Minimal detectable differences were smaller than differences observed in published studies for all measurements. DXA is a sensitive tool for detecting changes in peripheral fat among patients with HIV lipodystrophy...
  36. ncbi Individualized therapy for the treatment-experienced patient
    Sharon Walmsley
    Immunodeficiency Clinic, Toronto Hospital, University Health Network, University of Toronto
    AIDS Read 13:S11-5. 2003
    ..The selection of salvage therapy remains complex and needs to be individualized...
  37. ncbi CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy
    Marina B Klein
    Department of Medicine, Divisions of Infectious Diseases Immunodeficiency, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Contemp Clin Trials 29:617-30. 2008
    ..Effective prevention of a broad range of neuropsychiatric symptoms by citalopram has the potential to diminish PEG-IFN-alpha associated morbidity and consequently, allow a greater number of patients to complete full therapy...
  38. ncbi A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy
    Janet M Raboud
    University of Toronto, Toronto, Canada
    HIV Clin Trials 11:39-50. 2010
    ..To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue...
  39. ncbi First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach
    Isaac Bogoch
    Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
    Curr Opin HIV AIDS 4:493-8. 2009
    ..To provide a clinical approach for choosing an appropriate second-line antiretroviral (ARV) regimen in HIV-positive patients with virologic failure...
  40. ncbi Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada
    Michelle D Furler
    Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    AIDS Patient Care STDS 17:155-68. 2003
    ..CAM use in Canadian patients with HIV is extremely common, with higher use among women. The definition of CAM has a substantial impact both on reported prevalence rates and on predictors of CAM use...
  41. ncbi Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors
    Darrell Tan
    Division of Infectious Diseases, University of Toronto, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4
    HIV Clin Trials 7:107-15. 2006
    ..This cross-sectional study evaluated whether an association exists between mild symptoms and lactate levels...
  42. ncbi The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial
    Jill Tinmouth
    Department of Medicine, University of Toronto, Ontario, Canada
    Arch Intern Med 166:1178-83. 2006
    ..Empirical lactose avoidance is often advised despite lack of evidence of benefit in a population at risk for osteopenia and malnutrition...
  43. ncbi An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational database
    Janet Raboud
    Department of Medicine, University Health Network, University of Toronto, Ontario, Canada
    HIV Clin Trials 8:311-9. 2007
    ..This study was conducted to determine how frequently self-reported symptoms are captured as adverse drug events (ADEs) during chart abstraction...
  44. ncbi Systematic review of strategies to measure HIV-related diarrhea
    Jill Tinmouth
    Division of Gastroenterology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    HIV Clin Trials 8:155-63. 2007
    ..There is no gold standard to measure diarrhea, making comparison across trials difficult. We conducted a systematic review to determine current research practice in measuring HIV-related diarrhea...
  45. ncbi Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience
    Patrick Tang
    University of Toronto, Ont
    CMAJ 170:47-54. 2004
    ..In patients with SARS, specimens taken from the lower respiratory tract and stool samples test positive by means of RT-PCR more often than do samples taken from other areas...
  46. ncbi Evaluation of Stool frequency and stool form as measures of HIV-related diarrhea
    Jill Tinmouth
    Division of Gastroenterology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    HIV Clin Trials 8:421-8. 2007
    ..In the highly active antiretroviral therapy (HAART) era, HIV-related diarrhea remains common. Our aim was to evaluate stool frequency and form as measures of HIV-related diarrhea...
  47. ncbi SARS outbreak in the Greater Toronto Area: the emergency department experience
    Bjug Borgundvaag
    Mount Sinai Hospital, Toronto, Ont
    CMAJ 171:1342-4. 2004
  48. ncbi Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
    Christopher M Booth
    University of Toronto, Mount Sinai Hospital, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada
    JAMA 289:2801-9. 2003
    ..Although SARS is associated with significant morbidity and mortality, especially in patients with diabetes or other comorbid conditions, the vast majority (93.5%) of patients in our cohort survived...
  49. ncbi Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
    ....
  50. ncbi Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy
    Stephen D Shafran
    University of Alberta, Edmonton, Alberta, Canada
    Ann Intern Med 137:734-7. 2002
    ..S. Public Health Service/Infectious Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART...
  51. ncbi Clinical problem-solving. Where are you from?
    Kevin C Katz
    Department of Medicine, University of Toronto
    N Engl J Med 346:764-7. 2002
  52. ncbi Salvage antiretroviral therapy in HIV infection
    Mona R Loutfy
    Department of Medicine, Division of Infectious Diseases, University of Toronto, Canada
    Expert Opin Pharmacother 3:81-90. 2002
    ..It is important that new agents and new targets continue to be developed as an increasing number of patients in practice have exhausted all treatment options...
  53. ncbi Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores
    Sharon L Walmsley
    Toronto General Hospital, University of Toronto, Toronto, Canada
    AIDS 21:2245-8. 2007
    ..Tipranavir/ritonavir therapy improves treatment response rates compared with lopinavir/ritonavir in patients whose viruses have reduced susceptibility to lopinavir/ritonavir...
  54. ncbi CD4(+) cell count increase predicts clinical benefits in patients with advanced HIV disease and persistent viremia after 1 year of combination antiretroviral therapy
    Mona R Loutfy
    McGill University Health Centre, Montreal, Quebec, Canada
    J Infect Dis 192:1407-11. 2005
    ..A 25-cell/mm(3) increase in CD4(+) cell count was associated with a 21% reduction in the risk of an AIDS-defining event or death (P<.0001)...
  55. ncbi Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimen
    Mona R Loutfy
    Department of Medicine, University of Toronto, Toronto, Canada
    HIV Clin Trials 8:259-68. 2007
    ....
  56. ncbi Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens
    Mona R Loutfy
    Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University, Montreal, Que, Canada
    Antivir Ther 9:595-602. 2004
    ....
  57. ncbi Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients
    Martin S King
    Abbott Laboratories, Abbott Park, Illinois, USA
    J Infect Dis 190:280-4. 2004
    ..7-3.0; P<.001). For nelfinavir-treated patients, but not for lopinavir/ritonavir-treated patients, higher baseline HIV-1 RNA levels and lower baseline CD4 cell counts were associated with a higher risk of loss of virologic response...
  58. ncbi Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSista
    Charles B Hicks
    Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 368:466-75. 2006
    ....
  59. ncbi Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial
    Joseph Gathe
    Therapeutic Concepts, Houston, TX 77004, USA
    Clin Infect Dis 43:1337-46. 2006
    ....
  60. ncbi TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
    ..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
  61. ncbi Inclusion body myositis: another possible manifestation of antiretroviral-associated mitochondrial toxicity
    Mona R Loutfy
    AIDS 17:1266-7. 2003
  62. ncbi Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice
    David R Burdge
    Oak Tree Clinic, Children's and Women's Health Centre of British Columbia and University of British Columbia, Vancouver, BC
    CMAJ 168:1683-8. 2003
  63. ncbi Field evaluation of the Merlin immediate HIV-1 and -2 test for point-of-care detection of human immunodeficiency virus antibodies
    Stephen D Shafran
    Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada T6G 2B7
    Clin Infect Dis 34:658-61. 2002
    ..96%, and its overall accuracy was 99.96%. The Merlin POC test is highly accurate for the detection of HIV antibodies...
  64. ncbi Lipodystrophy severity does not contribute to HAART nonadherence
    Evan J Collins
    Immunodeficiency Clinic, Toronto General Hospital, Toronto, Canada
    AIDS Behav 10:273-7. 2006
    ..Remembering was most strongly related to adherence indicators, retaining statistical significance in adjusted multivariate regression analyses...
  65. ncbi Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines)
    David R Burdge
    Oak Tree Clinic, Children's and Women's Health Centre of British Columbia and University of British Columbia, Vancouver, BC
    CMAJ 168:1671-4. 2003